文拉法新缓释剂治疗86例广泛性焦虑症的临床对照研究

Clinic contrast study of Venlafaxine slow release for treatment of Generalized Anxiety disorder(GAD)

目的:评价文拉法新缓释剂治疗广泛性焦虑症的临床疗效和不良反应。方法:随机抽取86例广泛性焦虑症患者分为两组,分别服用文拉法新缓释剂或阿普唑仑,疗程8周。于治疗前及治疗后1、2、4、6、8周末进行汉密尔顿焦虑量表(HAMA)及副反应量表(TESS)评定疗效和不良反应。结果:文拉法新缓释剂与阿普唑仑疗效相似,文拉法新缓释剂起效时间比阿普唑仑快,不良反应少而轻,无成瘾性。结论:文拉法新缓释剂是治疗广泛性焦虑症的安全、起效快的药物。

Objective ：To assess the clinic efficacy and adverse reaction of Venlafaxine slow release for the treatment of generalized anxiety disorder （GAD）. Methods：86 patients with GAD were divided into two groups, and took Venlafaxine and Alprzolam separately in a treatment course for 8 weeks. Assess the efficacy and adverse reaction with HAMA and TESS before treatment and at the end of weeks 1, 2, 4, 6, and 8 after treatment. Results ： In contrast with Alprazolam, Venlafaxine has similar effect, fast reaction time, less side effect and no addiction. Conclusions： Venlafaxine slow release is a safe and fast effective medicine for the treatment of GAD.